MNK Oct 2019 28.000 call

OPR - OPR Delayed Price. Currency in USD
0.1000
0.0000 (0.00%)
As of 10:35AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.1000
Open0.1000
Bid0.0000
Ask0.5500
Strike28.00
Expire Date2019-10-18
Day's Range0.1000 - 0.1000
Contract RangeN/A
Volume2
Open InterestN/A
  • Is the Options Market Predicting a Spike in Mallinckrodt (MNK) Stock?
    Zacks

    Is the Options Market Predicting a Spike in Mallinckrodt (MNK) Stock?

    Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

  • Benzinga

    Opioid Drug Companies Rally On Hopes of Broader Settlement

    Shares of companies embroiled in the U.S. opioid crisis were trading sharply higher Wednesday following a Tuesday  Wall Street Journal report that said three opioid drug distributors are in talks with ...

  • PR Newswire

    Mallinckrodt to Report Earnings Results for Third Quarter 2019

    A conference call for investors will begin at 8:30 a.m. Eastern Time. Callers will need to provide the Conference ID of 6080969. Through an audio replay: A replay of the call will be available beginning at 11:30 a.m. Eastern Time on Tuesday, Nov. 5, 2019, and ending at 11:30 a.m. Eastern Time on Tuesday, Nov. 19, 2019.

  • J&J Settles Ahead of Multi-District Opioid Trial, Stock Up
    Zacks

    J&J Settles Ahead of Multi-District Opioid Trial, Stock Up

    J&J (JNJ) reaches settlement agreement with Cuyahoga and Summit counties in Ohio concerning the lawsuits pending in MDL.

  • American City Business Journals

    Why St. Louis stocks are trailing stocks nationally this year

    St. Louis stocks far underperformed the national stock indexes through the first three quarters of the year, but almost a third of the local companies were up 20% or more.

  • The Market Tells Opioid Drugmakers to Settle Up
    Bloomberg

    The Market Tells Opioid Drugmakers to Settle Up

    (Bloomberg Opinion) -- The markets are sending a message to drugmakers facing opioid litigation: Settle up.Johnson & Johnson late Tuesday announced its first legal settlement over the pharmaceutical giant’s alleged role in spurring the opioid crisis, a modest $20 million deal with two Ohio counties. The agreement will see it avoid a risky trial later this month and the company’s stock rose as much as 3.6% in early trading. J&J’s deal came a day after a report that drugmakers may use Purdue Pharma’s bankruptcy as a model for a broader settlement, news that briefly boosted smaller companies including Mallinckrodt PLC, Teva Pharmaceutical Industries Ltd, and Endo International PLC. The profusion of litigation, the size of the addiction crisis, and public fury have created a liability of unknown size that could take years to resolve. Thousands of lawsuits remain, and a global deal that resolves a big chunk of those suits will be challenging to negotiate. J&J’s settlement cracks the door, however, and investors want resolution. Getting something done and moving on should be a priority for drugmakers over pinching pennies.  Banding together could help ensure that no drugmaker would be left behind to fight through every lawsuit or face a potential liability disproportionate to its relative role in the crisis. It won’t be cheap, and it won’t be easy, but it would be worth the effort.A global settlement, even if it involves a substantial cash payout, would go a long way toward helping drugmakers move forward from the crisis, while investors would finally be able to put a number on the liability instead of fearing the uncertain result of every individual trial. A settlement also could reduce the risk of bankruptcy for indebted members of the group, cutting another asymmetric risk. As for the other side, the parties affected by the crisis should fight aggressively for a large settlement. The amount of money needed to combat the crisis and build a real treatment infrastructure in America demands it. Beyond that, it’s worth fighting for a figure large enough to deter the kind of behavior and negligence that allegedly spurred the crisis. That doesn’t mean they should disdain a global settlement and the idea of compromise. A broad deal may be governments' best avenue to get cash quickly so they can help people in need as soon as possible. Stretching the fight out may not result in a larger payout, and could result in some communities getting nothing. We’re still a long way from a significant deal; many states oppose even the single-company version of Purdue’s bankruptcy. Hopefully, both sides will realize the benefits of avoiding a multi-year battle and make further progress. To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • JNJ moves to dodge opioid bullets, but other drug names face uncertainty
    Yahoo Finance

    JNJ moves to dodge opioid bullets, but other drug names face uncertainty

    Opioid litigation increasingly affecting credit outlooks for drug makers and distributors.

  • Opioid Makers Gain on View They’ll Use Purdue Deal as Model
    Bloomberg

    Opioid Makers Gain on View They’ll Use Purdue Deal as Model

    (Bloomberg) -- Makers of prescription painkillers are climbing higher after Dow Jones reported that the companies are looking to use Purdue Pharma LP’s bankruptcy as a model to settle their own lawsuits.Mallinckrodt Plc and Endo International Plc jumped Tuesday morning as Wall Street gauged what shape their settlements might take. The two, plus drugmaker Teva Pharmaceutical Industries Ltd., are facing similar claims related to their role in sparking the opioid crisis.Shares of Mallinckrodt and Endo rose by at least 10% while Teva gained a much as 7.1%. Mallinckrodt has shed more than 90% of its market value in the past year and Endo and Teva are down 78% and 66%, respectively.Companies that distributed opioids -- McKesson Corp., Cardinal Health Inc. and AmerisourceBergen Corp. -- edged higher as the Purdue idea may signal progress in resolving lawsuits.(Updates share movement in third, fourth paragraph)To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Scott SchnipperFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Mallinckrodt Up on Settlement Agreement With Ohio Counties
    Zacks

    Mallinckrodt Up on Settlement Agreement With Ohio Counties

    Mallinckrodt (MNK) gains on the execution of a settlement agreement with Cuyahoga and Summit Counties in Ohio concerning the lawsuits pending in MDL.

  • PR Newswire

    Mallinckrodt Announces Positive Top-Line Findings from its Observational Registry Assessing Relapse Recovery in Multiple Sclerosis Relapse Patients Treated with Acthar® Gel (Repository Corticotropin Injection)

    STAINES-UPON-THAMES, United Kingdom, Oct. 1, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a global biopharmaceutical company, today announced positive top-line findings from its observational registry to assess treatment patterns and response to Acthar® Gel (repository corticotropin injection) in reducing the clinical impact of disease exacerbations in patients with multiple sclerosis (MS) relapse. Mallinckrodt plans to share the data at an upcoming medical meeting. MS is a chronic, degenerative disease that can cause numerous impairments, including fatigue, balance/coordination issues, numbness or tingling, vision problems, muscle spasms, tremors and emotional changes, and some people with MS experience relapses while on standard therapies1.

  • Drugmakers look to use Purdue Pharma's bankruptcy to settle U.S. opioid suits: WSJ
    Reuters

    Drugmakers look to use Purdue Pharma's bankruptcy to settle U.S. opioid suits: WSJ

    Endo, J&J, Teva Pharmaceutical Industries Ltd, Allergan Plc and Mallinckrodt Plc - are looking to enact a global settlement of the litigation that would be implemented through Purdue's Chapter 11 case, the WSJ reported, citing a person familiar with the matter. The mechanism, if successful, would allow the companies to contribute money into a trust set up through the bankruptcy in exchange for a complete release from liability, according to the report.

  • Reuters

    UPDATE 1-Drugmakers look to use Purdue Pharma's bankruptcy to settle U.S. opioid suits -WSJ

    Endo International Plc, Johnson & Johnson and other drugmakers that face litigation over the opioid crisis are exploring a way to settle the cases by participating in Purdue Pharma LP's bankruptcy, the Wall Street Journal reported, citing internal documents and a person familiar with the matter. Five drugmakers battling the cases - Endo, J&J, Teva Pharmaceutical Industries Ltd, Allergan Plc and Mallinckrodt Plc - are looking to enact a global settlement of the litigation that would be implemented through Purdue's Chapter 11 case, the WSJ reported, citing a person familiar with the matter.

  • Blackstone, Mallinckrodt, Amazon, Walmart: Companies to watch
    Yahoo Finance

    Blackstone, Mallinckrodt, Amazon, Walmart: Companies to watch

    The Blackstone Group, Mallinckrodt, Amazon, Walmart, General Motors and Universal are the companies to watch.

  • Barrons.com

    Mallinckrodt Stock Is Rising on Opioid Settlement

    (MNK) shares rose Monday morning as the drugmaker said it had completed an opioid settlement announced in early September. The $30 million deal releases Mallinckrodt from a federal trial set to begin Oct. 21, in which the Ohio counties of Cuyahoga and Summit are pursuing more than a dozen pharmaceutical companies involved in the manufacture and sale of opioids. In early trading, Mallinckrodt’s stock (ticker: MNK) was up 2.5%, to $2.30.

  • MarketWatch

    Mallinckrodt stock surges after agreement to pay $24 million to Ohio counties as part of opioid litigation settlement

    Shares of Mallinckrodt PLC surged 4% in premarket trading Monday, after the drug maker said it reached a settlement agreement in connection with opioid litigation with the Ohio counties of Cuyahoga and Summit, in which the drug maker will pay $24 million in cash, provide $6 million in generic products and provide a $500,000 payment in two years in recognition of the counties' time and expenses. Under terms of the agreement, all named Mallinckrodt entities will be dismissed with prejudice from the lawsuit, and the value of the settlement should not be extrapolated to any other opioid-related claims. The stock has plunged 75.5% over the past three months while the S&P 500 has gained 0.7%.

  • PR Newswire

    Mallinckrodt Finalizes Settlement to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit

    Under the agreement, Mallinckrodt will pay $24 million in cash and provide $6 million in generic products, including addiction treatment products. It also will provide a $500,000 payment in two years in recognition of the counties' time and expenses.  Further, in the event of a comprehensive resolution of government-related opioid claims, Mallinckrodt has agreed that the two plaintiff counties will receive the value they would have received under such a resolution, less the payments described above. "Mallinckrodt is pleased to finalize this settlement agreement with the Cuyahoga and Summit Counties," said Mark Casey, Executive Vice President and Chief Legal Officer of Mallinckrodt.

  • Lone Mallinckrodt Bull Undaunted After Share Price Tumbles 94%
    Bloomberg

    Lone Mallinckrodt Bull Undaunted After Share Price Tumbles 94%

    (Bloomberg) -- Mallinckrodt Plc investors don’t have a lot to be hopeful about as the pharmaceutical company’s stock continues to flounder after losing almost all of its value over the past four years.Thousands of opioid lawsuits, a pricing dispute with U.S. regulators and looming bond maturities have raised bankruptcy concerns. Once a standout worth more than $15 billion in 2015, Mallinckrodt’s market value has shrunk to $200 million. Wall Street has essentially left it for dead, but for a lone bull who’s kept her buy rating despite the beating the stock, and her call, have taken.Cantor Fitzgerald’s Louise Chen has recommended buying Mallinckrodt since 2017. Shares have fallen 94% since she first made that call. The analyst -- whose overall track record has been mixed, with more misses than hits -- has an $18 price target, 600% above the current price.In her view, Mallinckrodt suffers from “a perception problem” that ties it to the pains of the U.S. pharmaceutical industry, Chen wrote in a note last month. “There is a lot of value to be unlocked.”Chen, who has declined interview requests, sees value in Mallinckrodt’s pipeline, which to be sure has had some good developments lately. Favorable results from two recent studies have boosted the shares and earned praise from other analysts.While Chen, and management, see the new therapies possibly offsetting losses from existing medicines, others say it won’t be enough. The drugs “will not sufficiently diversify the business away from Acthar,” the blockbuster autoimmune and rare-diseases treatment, Piper Jaffray’s David Amsellem said.Sales of Acthar, which has faced pricing scrutiny, have been sliding since 2016 as health insurers tightened reimbursements and prescriptions went unfilled. After a 9% decline last quarter, management said sales may not exceed $1 billion this year for the first time Mallinckrodt acquired it in 2014.In August, the drugmaker lost an appeals court bid over its second-largest drug, INOmax, which could see a 15% to 10% decline in sales over the next two years, according to Wells Fargo. Its third-best seller, Ofirmev, is expected to lose market exclusivity in 2021.“There’s pressure on the top line, there’s pressure on cash flows,” Amsellem said. “Layer in the high debt levels, the opioid-related liabilities, the Acthar-related liabilities, and that puts us in the situation we have today.”With about $5 billion in debt, analysts have estimated that Mallinckrodt could owe as much as $600 million to the U.S. government over Acthar rebates. It’s also among the companies facing potential liability into the tens of billions of dollars for their role in the opioid crisis.While it can probably handle the government fines and address its 2020 bond maturities, “the concern is what happens with opioid fines,” Bloomberg Intelligence credit analyst Mike Holland said.Chief Executive Officer Mark Trudeau reminded investors recently that for now, opioid fines are “only litigation risk, no litigation liability.” He said reports of potential restructuring and bankruptcy were “wild speculation.”Mallinckrodt representatives didn’t immediately respond to requests for comment on Wednesday.While only eight of the 27 stocks currently under her purview are in the green since she started covering them, Chen has had one really big win: Amarin Corp Plc has surged more than 300% on a promising heart pill.\--With assistance from Katherine Doherty.To contact the reporter on this story: Tatiana Darie in New York at tdarie1@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Richard RichtmyerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • 5 Stocks That Could Get Crushed By Opioid Lawsuit Tidal Wave
    Investopedia

    5 Stocks That Could Get Crushed By Opioid Lawsuit Tidal Wave

    Stock investors who think their portfolios escaped the wave of lawsuits stemming from the opioid crisis should look again. While privately-owned Purdue Pharma has suffered nearly all the bad press and financial damage thus far, five major public companies could still face tens of billions in liabilities that threaten to wipe out big chunks of their market value. “Momentum has picked up significantly,” said Abbe Gluck, a professor of law at Yale University.

  • ACCESSWIRE

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of MMM, MNK and IFF

    CEDARHURST, NY / ACCESSWIRE / September 24, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.

  • Newsfile

    MALLINCKRODT DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm

    New York, New York--(Newsfile Corp. - September 24, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company")  of the September 24, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Mallinckrodt stock or options between February 28, 2018 and July 16, 2019 and ...

  • ACCESSWIRE

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of MNK, IFF and VAL

    CEDARHURST, NY / ACCESSWIRE / September 24, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.

  • Mallinckrodt's StrataGraft Tissue Phase III Data Positive
    Zacks

    Mallinckrodt's StrataGraft Tissue Phase III Data Positive

    Mallinckrodt's (MNK) experimental StrataGraft regenerative tissue meets goals in a late-stage study for the treatment of burns.

  • Business Wire

    TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mallinckrodt plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mallinckrodt plc (“Mallinckrodt” or “the Company”) (NYSE: MNK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • Companies to Watch: Blackstone looks to expand, Mallinckrodt reaches settlement in opioid crisis, record weekend for Amazon and Walmart
    Yahoo Finance Video

    Companies to Watch: Blackstone looks to expand, Mallinckrodt reaches settlement in opioid crisis, record weekend for Amazon and Walmart

    The Blackstone Group, Mallinckrodt, Amazon, Walmart, General Motors and Universal are the companies to watch.